Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.
J Hill, TF Lindsay, F Ortiz, CG Yeh… - … (Baltimore, Md.: 1950 …, 1992 - journals.aai.org
J Hill, TF Lindsay, F Ortiz, CG Yeh, HB Hechtman, FD Moore Jr
Journal of immunology (Baltimore, Md.: 1950), 1992•journals.aai.orgWe examined the role of C activation in ischemia reperfusion injury by inhibiting C activation
in a rat model of mesenteric arterial occlusion. In anesthetized rats, 60 min of mesenteric
arterial occlusion was followed by 3 h of reperfusion. PBS alone or containing soluble C
receptor 1 (3 or 6 mg) was administered iv Controls underwent laparotomy without ischemia.
Relative serum C activities were assessed by hemolytic assay, neutrophil
(polymorphonuclear leukocyte) sequestration by tissue content of myeloperoxidase (MPO) …
in a rat model of mesenteric arterial occlusion. In anesthetized rats, 60 min of mesenteric
arterial occlusion was followed by 3 h of reperfusion. PBS alone or containing soluble C
receptor 1 (3 or 6 mg) was administered iv Controls underwent laparotomy without ischemia.
Relative serum C activities were assessed by hemolytic assay, neutrophil
(polymorphonuclear leukocyte) sequestration by tissue content of myeloperoxidase (MPO) …
Abstract
We examined the role of C activation in ischemia reperfusion injury by inhibiting C activation in a rat model of mesenteric arterial occlusion. In anesthetized rats, 60 min of mesenteric arterial occlusion was followed by 3 h of reperfusion. PBS alone or containing soluble C receptor 1 (3 or 6 mg) was administered i.v. Controls underwent laparotomy without ischemia. Relative serum C activities were assessed by hemolytic assay, neutrophil (polymorphonuclear leukocyte) sequestration by tissue content of myeloperoxidase (MPO) activity, intestinal mucosal injury by histologic grading, lung vascular permeability by the ratio of bronchoalveolar lavage to blood concentration of radiolabeled BSA, and endothelial cell injury was quantified by measurement of plasma factor VIII-related Ag. After reperfusion, PBS-treated animals had increased intestinal MPO (0.048 +/- 0.007 U/g) compared to sham (0.022 +/- 0.005 U/g (p less than 0.05)) and intestinal mucosal injury score (2.490 +/- 0.221) compared to sham (0.331 +/- 0.045 (p less than 0.05)). Treatment with 6 mg soluble C receptor 1 15 min before reperfusion reduced intestinal MPO (0.017 +/- 0.003 U/g (p less than 0.05)) and mucosal injury (1.733 +/- 0.168 (p less than 0.05)) compared to PBS control. PBS-treated animals also demonstrated increased lung MPO (0.314 +/- 0.025 U/g vs 0.085 +/- 0.018 in sham (p less than 0.05)) and increased lung permeability (bronchoalveolar lavage/blood cpm 11.32 +/- 1.35 x 10(-3) vs sham 2.22 +/- 0.19 x 10(-3) (p less than 0.05)). Treatment with 6 mg soluble C receptor 1 15 min before reperfusion or at reperfusion reduced the lung permeability (bronchoalveolar lavage/blood cpm 3.90 +/- 0.79 x 10(-3) and 5.08 +/- 0.75, respectively (both p less than 0.05)) compared to PBS control, but did not reduce lung MPO (0.342 +/- 0.031 U/g and 0.246 +/- 0.025), respectively. Treatment with sCR1 also reduced the release of factor VIII-related Ag, 5-day mortality, and C hemolytic activity. In this model, C is a major mediator of intestinal injury and extraintestinal injury.
journals.aai.org